Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
BMC Infectious Diseases, doi:10.1186/s12879-021-06348-5
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease patients. Objective: To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19. Design, setting and participants: A randomized, double-blind, placebo-controlled study was conducted in nonhospitalized individuals with COVID-19 in Corrientes, Argentina. Patients with SARS-CoV-2 positive nasal swabs were contacted within 48 h by telephone to invite them to participate. The trial randomized 501 patients between August 19th 2020 and February 22nd 2021. Intervention: Patients were randomized to ivermectin (N = 250) or placebo (N = 251) arms in a staggered dose, according to the patient's weight, for 2 days. Main outcomes and measures: The efficacy of ivermectin to prevent hospitalizations was evaluated as primary outcome. We evaluated secondary outcomes in relationship to safety and other efficacy end points.
Supplementary Information The online version contains supplementary material available at https://doi. org/10.1186/s12879-021-06348-5.
Additional file 1.
Declarations Ethics approval and consent to participate study authorized by Health Sciences Research Bioethics Committee (HSRBC) of the National University of the Northeast (UNNE) Faculty of Medicine, Argentina (Resolution 21/20 on August 17th, 2020). The consent to participate in the trial was approved by HSRBC of the UNNE. The study was performance in accordance with the Declaration of Helsinki and all methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all participants prior to the study. The study has been supervised by a Steering Committee and Safety Committee.
Consent for publication Not Applicable.
Competing interests The authors declare that they have no competing interests.
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ahmed, Hany, Youssef, Hany, Hafez et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic, doi:10.21203/rs.3.rs-100956/v1
Al-Abdouh, Bizanti, Barbarawi, Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials, Contemp Clin Trials, doi:10.1016/j.cct.2021.106272
Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double blind dose response study in Lagos. medRxiv, doi:10.1101/2021.01.05.21249131
Bartoli, Gabrielli, Alicandro, Nascimbeni, Andreoni, COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs, Intern Emerg Med, doi:10.1007/s11739-020-02569-9
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19 -final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Camprubí, Almuedo-Riera, Martí-Soler, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PLoS One
Chaccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebocontrolled, randomized clinical trial, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
Gotz, Magar, Dornfeld, Influenza a viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep, doi:10.1038/srep23138
Hashim, Maulood, Rasheed, Dhurgham, Fatak et al., Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq medRxiv Preprint, doi:10.1101/2020.10.26.20219345
Khan, Khan, Debnath, Nath, Mahtab et al., Ivermectin treatment may improve the prognosis of patients with COVID
Lai, Liu, Wang, Wang, Hsueh et al., Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths, J Microbiol Immunol Infect, doi:10.1016/j.jmii.2020.02.012
Libster, Marc, Wappner, Coviello, Bianchi et al., Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med, doi:10.1056/NEJMoa2033700
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2021.3071
Mahmud, Rahman, Alam, Ahmed, Kabir et al., Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J Int Med Res, doi:10.1177/03000605211013550
Mega, Latin America's embrace of an unproven COVID treatment is hindering drug trials, Nature
Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and metaanalysis, J Antimicrob Chemother, doi:10.1093/jac/dkz524
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis, J Pharm Pharm Sci, doi:10.18433/jpps31457
Ross, Clemens, Sumiya, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191
Salama, Han, Yau, Reiss, Kramer et al., Tocilizumab in patients hospitalized with Covid-19 pneumonia, N Engl J Med, doi:10.1056/NEJMoa2030340
Simonovich, Pratx, Scibona, Beruto, Vallone et al., A randomized trial of convalescent plasma in Covid-19 severe pneumonia, N Engl J Med, doi:10.1056/NEJMoa2031304
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir Res, doi:10.1016/j.antiviral.2013.06.002
Vallejos, Zoni, Bangher, Villamandos, Bobadilla et al., Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial, Trials, doi:10.1186/s13063-020-04813-1
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin alpha/betamediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 inWuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3